Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion’s president and chief executive officer, will present at the Credit Suisse Healthcare Conference in Scottsdale, Ariz. The presentation will take place on Tuesday, November 12, at 8 a.m. MST/11:00 a.m. EST.
Help employers find you! Check out all the jobs and post your resume.
